Success Stories: A Postdoctoral Fellow in Molecular Medicine Secures EB1A Approval in Just 8 Days via the Premium Processing
Client’s Testimonial:
“I had an excellent experience working with Chen Immigration Law associates on my EB1A green card application. Their team was highly knowledgeable, responsive, and thorough throughout the entire process. The portal is full of useful information and easy to use. They helped present my case in the strongest possible way, guiding me step by step with clear communication and expert advice. Thanks to their dedication and strategic approach, my petition was approved smoothly. I highly recommend Chen Immigration Law associates to anyone pursuing an EB1A or other immigration path.”
On May 8th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Fellow in the Field of Molecular Medicine (Approval Notice).
General Field: Molecular Medicine
Position at the Time of Case Filing: Postdoctoral Fellow
State of Residence at the Time of Filing: New York
Approval Notice Date: May 8th, 2025
Processing Time: 8 days (Premium Processing Requested)
Case Summary:
A distinguished postdoctoral fellow, working in the field of molecular medicine, recently secured approval for his I-140 petition under the EB-1A (Alien of Extraordinary Ability) category. Filed with the direct premium processing, the petition was approved in just 8 days, highlighting the exceptional strength of his academic and research credentials.
Recognized as a thought leader in nanomedicine and immunology
Our client’s research spans targeted cancer therapy, RNA-based therapeutics, and chronic inflammatory disease treatment, placing him among the top contributors in these rapidly evolving fields. His work has resulted in major scientific breakthroughs, particularly in delivering RNA and CRISPR-based therapeutics using lipid nanoparticle platforms.
After he reached our law firm, our team developed a strategy that demonstrated his sustained acclaim and documented record of original contributions, showing how his innovations have been widely cited, implemented, and advanced by the global scientific community.
Achievements that position him at the top of his field
In support of the EB1A petition, we documented the following case highlights:
● 20 peer-reviewed journal articles (7 first-authored), 2 scientific abstracts, and 2 book chapters, with at least one first-authored in each category, many of which appeared in top-tier journals, showcasing his exceptional publication record
● 4,265 total citations, demonstrating the global impact and sustained relevance of his research
● At least 12 papers ranked among the most highly cited in Molecular Biology & Genetics for their year of publication
● h-index of 17, placing him in the top 3% of authors in medicine
● Completed 30+ peer reviews for journals such as Science Immunology, Trends in Biotechnology, and Journal of Controlled Release
● Served as guest editor for special issues in Nanotechnology and the International Journal of Molecular Sciences
● Research supported by prestigious institutions including the NIH, European Research Council, Israel Science Foundation, and Israel Cancer Research Fund
A proposed endeavor aligned with U.S. biomedical prioritiesOur client plans to continue innovating in molecular therapeutics, particularly through the development of RNA-delivery platforms and immunomodulatory therapies. His goal is to further optimize gene and protein delivery technologies to treat cancer and inflammatory diseases, contributing to national objectives in precision medicine and pharmaceutical innovation.
Expert testimonials confirm national importance
The petition included four recommendation letters, with three written by independent experts unaffiliated with the client. These letters affirmed the originality of his contributions and the importance of his research to national biomedical goals. One expert stated:
“[Client’s] research in RNA-based molecular therapy, which uses LNPs to target immune cells, is improving treatment precision. He developed a way to selectively deliver RNA therapies directly to disease-causing immune cells, improving outcomes in colitis and other inflammatory conditions. Physicians and researchers in the U.S. are actively using these insights to develop patient-specific therapies that reduce reliance on broad-spectrum immunosuppressants. Overall, [client] is shaping precision medicine, facilitating the development of more effective, personalized, and safer treatments, thus making him an indispensable asset to the United States.”
EB1A approved in only 8 daysWe are proud to announce that the client’s EB1A petition was approved just 8 days after submission, thanks to the strength of the petition and the use of the premium processing. We congratulate him on this well-earned success and are honored to support his continued contributions to the future of biomedical research in the United States.